Universidade Federal do Ceará, Programa de Pós-Graduação em Saúde Coletiva, Fortaleza, CE, Brazil; Universidade Federal do Ceará, Departamento de Saúde Comunitária, Fortaleza, CE, Brazil.
Universidade Federal do Ceará, Departamento de Saúde Comunitária, Fortaleza, CE, Brazil.
Braz J Infect Dis. 2018 Mar-Apr;22(2):92-98. doi: 10.1016/j.bjid.2018.03.001. Epub 2018 Mar 27.
Visceral Leishmaniasis is the most severe form of disease caused by the Leishmania donovani complex, with significant morbidity and mortality in developing countries. Worse outcomes occur among HIV-positive individuals coinfected with Leishmania. It is unclear, however, if there are significant differences on presentation between Visceral Leishmaniasis patients with or without HIV coinfection.
We reviewed medical records from adult patients with Visceral Leishmaniasis treated at a reference healthcare center in Fortaleza - Ceará, Brazil, from July 2010 to December 2013. Data from HIV-coinfected patients have been abstracted and compared to non-HIV controls diagnosed with Visceral Leishmaniasis in the same period.
Eighty one HIV-infected patients and 365 controls were enrolled. The diagnosis in HIV patients took significantly longer, with higher recurrence and death rates. Kala-azar's classical triad (fever, constitutional symptoms and splenomegaly) was less frequently observed in Visceral Leishmaniasis-HIV patients, as well as jaundice and edema, while diarrhea was more frequent. Laboratory features included lower levels of hemoglobin, lymphocyte counts and liver enzymes, as well as higher counts of blood platelets and eosinophils. HIV-infected patients were diagnosed mainly through amastigote detection on bone marrow aspirates and treated more often with amphotericin B formulations, whereas in controls, rK39 was the main diagnostic tool and pentavalent antimony was primarily used for treatment.
Clinical and laboratory presentation of Visceral Leishmaniasis in HIV-coinfected patients may differ from classic kala-azar, and these differences may be, in part, responsible for the delay in diagnosing and treating leishmaniasis, which might lead to worse outcomes.
内脏利什曼病是由利什曼原虫复合体引起的最严重疾病形式,在发展中国家具有较高的发病率和死亡率。在 HIV 阳性个体合并感染利什曼原虫时,结果更差。然而,尚不清楚 HIV 合并感染与不合并感染内脏利什曼病患者的临床表现是否存在显著差异。
我们回顾了 2010 年 7 月至 2013 年 12 月在巴西福塔莱萨的一家参考医疗中心治疗的成年内脏利什曼病患者的病历。从 HIV 合并感染患者中提取的数据,并与同期诊断为内脏利什曼病的非 HIV 对照患者进行比较。
共纳入 81 例 HIV 感染患者和 365 例对照患者。HIV 患者的诊断时间明显延长,复发率和死亡率更高。内脏利什曼病-HIV 患者中较少出现利什曼热的经典三联征(发热、全身症状和脾肿大),黄疸和水肿也较少见,而腹泻更常见。实验室特征包括较低的血红蛋白、淋巴细胞计数和肝酶水平,以及较高的血小板和嗜酸性粒细胞计数。HIV 感染患者主要通过骨髓抽吸物中的利什曼原虫检测进行诊断,并且更常使用两性霉素 B 制剂进行治疗,而在对照组中,rK39 是主要的诊断工具,五价锑主要用于治疗。
HIV 合并感染患者内脏利什曼病的临床和实验室表现可能与经典黑热病不同,这些差异可能部分导致利什曼病的诊断和治疗延迟,从而导致更差的结果。